Abstract

One of the most feared side effects of contemporary cataract surgery is still endophthalmitis. Prophylactic measures include the use of antibiotics: topical, subconjunctival, and intracameral, to avoid endophthalmitis. Moxifloxacin 0.5% has been used most frequently in preventive late-stage regimens. Objective: To ascertain how well moxifloxacin prevented endophthalmitis in patients having cataract surgery. Methods: This was a descriptive case study and was conducted at Eye Departments of Allama Iqbal Medical College, Jinnah Hospital, Lahore and Ameer-ud-Din Medical College, Lahore General Hospital, Lahore. The study was commenced after approval of the synopsis and completed in 6 months. Results: In this study, 23.75%(n=19) were between 40-50 years, 61.25%(n=49) between 51-60 years and 15%(n=12) had >60 years of age, and their average was calculated as 53.99+6.22 years. 58.76%(n=47) were males and 41.25%(n=33) were females in the study. Mean endothelial cell count before cataract surgery was calculated as 2776 +177 while post-operative the average endothelial count was calculated as 2424 +72.8. while the frequency of effect of moxifloxacin, in the prevention of endophthalmitis in patients undergoing cataract surgery was recorded as 22.5%(n=18) while 77.5%(n=62) had no effect of moxifloxacin while preventing endophthalmitis in patients undergoing cataract surgery. Conclusions: We conclude that the effect of moxifloxacin, in preventing endophthalmitis in patients undergoing phacoemulsification surgery is not significantly higher and may be used in our setup for prevention of endophthalmitis, being a risk factor for blindness. Moxifloxacin does not affect the corneal endothelial cells significantly.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call